In short
This article discusses a clinical trial investigating the long-term safety and effects of Valoctocogene Roxaparvovec, also known as Roctavian or BMN 270, in patients with severe hemophilia A. The study aims to evaluate the drug's long-term safety, its impact on bleeding rates, and its effects on patients' quality of life. This follow-up study involves participants who have previously received the drug in other BioMarin clinical trials.
At a glance
- Study Type
- Long-term follow-up (Phase IV)
- Drug Name
- Valoctocogene Roxaparvovec (Roctavian, BMN 270)
- Target Condition
- Severe Hemophilia A
- Main Objective
- Evaluate long-term safety
- Secondary Objectives
- Assess long-term effects, use of hemostatic agents, impact on quality of life
- Study Duration
- ≥ 10 years
- Key Outcomes
- Adverse events, bleeding rates, Factor VIII activity, use of other medications, quality of life measures
- Eligibility
- Participants from previous BioMarin clinical trials of Valoctocogene Roxaparvovec
What is Valoctocogene Roxaparvovec?
Valoctocogene roxaparvovec, also known by its brand name Roctavian, is a groundbreaking gene therapy designed to treat severe hemophilia A. This innovative treatment is also referred to by several other names, including BMN 270, AAV-hFVIII-SQ, and BMN-270. Hemophilia A is a genetic disorder that affects blood clotting, leading to prolonged bleeding and easy bruising.
How Does It Work?
Valoctocogene roxaparvovec uses a modified virus (called an adeno-associated virus) to deliver a functional copy of the blood-clotting factor VIII gene to the patient's liver cells. This gene therapy aims to enable the body to produce its own factor VIII, potentially reducing or eliminating the need for regular factor VIII replacement therapy.
Clinical Trial Information
A long-term follow-up study (Study 270-401, also known as GENEr8-LTE) is being conducted to evaluate the safety and effectiveness of valoctocogene roxaparvovec in patients with severe hemophilia A who have previously received the treatment in other BioMarin clinical trials.
Eligibility Criteria
To participate in this long-term follow-up study, patients must meet certain criteria:
- Have completed or be currently enrolled in a primary treatment study with valoctocogene roxaparvovec
- Be capable of giving informed consent
- Be in generally good health, without any conditions that would prevent full compliance with the study requirements
Study Objectives
The main objectives of this long-term follow-up study include:
- Evaluating the long-term safety of valoctocogene roxaparvovec
- Assessing the long-term effects of the treatment in hemophilia A patients
- Monitoring the use of other hemostatic agents (medications that help control bleeding)
- Evaluating the long-term impact on the patients' quality of life
Safety Monitoring
The study will closely monitor participants for any adverse reactions or events, with special attention to:
- Hepatotoxicity: Potential liver damage
- Thromboembolic events: Blood clots that could block blood vessels
- Development of factor VIII inhibitors: Antibodies that could interfere with the treatment
- Potential transmission to third parties
- Theoretical risk of tumorigenesis: The possibility of tumor formation
Potential Benefits
The study will assess several potential benefits of valoctocogene roxaparvovec, including:
- Changes in the annual bleeding rate
- Factor VIII activity levels over time
- Reduction in the use of other hemostatic medications
- Improvements in the patients' quality of life
Administration
Valoctocogene roxaparvovec is administered as a single intravenous infusion. The solution for infusion contains 2 × 10^13 vector genomes per milliliter. It's important to note that this is a one-time treatment, and no additional dosing will occur during the long-term follow-up study.
Patients enrolled in this study will be monitored through regular check-ins, which may include phone calls, remote visits, or site visits, conducted quarterly for at least 10 years. This long-term follow-up is crucial to understand the lasting effects and safety of this innovative gene therapy.